CD44 Standard Isoform; Not a Good Marker for Colon Cancer

Rohani, Pantea; Noroozinia, Farahnaz; Modarresi, Parisa; Abbasi, Ata

doi:10.5812/ijcm.9166

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these studies, 30 studies that evaluated the prognostic role of CD44 in CRC patients were in accordance with the inclusion criteria (24–28, 34–57, 66). Thirty four studies reported the association of CD44 expression with clinicopathological features (24, 26, 27, 35, 39–42, 44, 46, 47, 49, 52, 54, 57, 67–84).…”

Section: Resultsmentioning

confidence: 99%

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: CD44 is widely used as a putative cancer stem cells (CSCs) marker for colorectal cancer (CRC). However, the prognostic role of CD44 in CRC remains controversial. Methods: We performed a systematic review and meta-analysis to evaluate the association of various CD44 isoforms and overall survival (OS) and clinicopathological features of CRC patients. Results: A total of 48 studies were included in the meta-analysis. Total CD44 isoforms overexpression was significantly correlated with worse OS of patients with CRC (HR = 1.32, 95% CI = 1.08–1.61, P = 0.007). In a stratified analysis, a higher level of either CD44v6 or CD44v2 had an unfavorable impact on OS (HR CD44v6 = 1.50, 95% CI = 1.10–2.14, P = 0.010; HR CD44v2 = 2.93, 95% CI = 1.49–5.77, P = 0.002). Additionally, CD44 was shown to be associated with some clinicopathological features, such as lymph node metastasis (OR CD44 = 1.56, 95% CI = 1.01–2.41, P = 0.044; OR CD44v6 = 1.97, 95% CI = 1.19–3.26, P = 0.008; OR Total CD44 isoforms = 1.57, 95% CI = 1.15–2.14, P = 0.004), distant metastasis (OR CD44 = 2.90, 95% CI = 1.08–7.83, P = 0.035; OR Total CD44 isoforms = 1.89, 95% CI = 1.02–3.53, P = 0.044). Moreover, a high level of CD44 showed a possible correlation with poor differentiation (OR Total CD44 isoforms = 1.44, 95% CI = 1.00–2.08, P = 0.051), elevated level of CD44v6 tend to be correlated with tumor size (OR = 1.71, 95% CI = 0.99–2.96, P = 0.056). Conclusions: This meta-analysis demonstrated that CD44 overexpression might be an unfavorable prognostic factor for CRC patients and could be used to predict poor differentiation, lymph node metastasis and distant metastasis.

show abstract

Section: Resultsmentioning

confidence: 99%

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our study did not show any significant correlation between CD44, DCLK1, and ANXA2 expression and clinicopathological features of colorectal cancer and OS. Recent studies have also demonstrated no significant association between CD44 and tumoral characteristics of CRC (Rohani et al 2017 ; Wang et al 2019 ). However, some studies have shown that CD44 overexpression has been correlated with worse OS of patients with CRC (Wang et al 2019 , 2017 ).…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer

Gzil

Zarębska

Jaworski

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Introduction Colorectal cancer (CRC) constitutes one of the most prevalent malignancies in the world. Recent research suggests that cancer stem cells (CSCs) are responsible for tumor cell's malignant behavior in CRC. This study has been designed to determinate clinical implications of CSC markers: CD44, DCLK1, Lgr5, and ANXA2 in CRC. Materials and methods The study was performed on tissue samples which were collected from 89 patients undergoing colectomy. Formalin-fixed paraffin-embedded tissue blocks with representative tumor areas were identified and corded. Immunohistochemical staining was performed using anti-CD44, anti-LGR5, anti-ANXA2, and anti-DCLK1 antibodies. The H-score system was utilized to determine the immunointensity of CRC cells. Results The lower expression of Lgr5 was significantly correlated with the presence of lymph-node metastases (p = 0.011), while high expression of Lgr5 was statistically significant in vascular invasion in examined cancer tissue samples (p = 0.027). Moreover, a high H-score value of Lgr5 expression was significantly related to a reduced overall survival rate (p = 0.043). Conclusion Our results suggest a strong relationship between CSC marker Lgr5 and vascular invasion, presence of lymphnode metastasis, and overall poor survival. The presence of Lgr5 might be an unfavorable prognostic factor, and its high level in cancer tissue is related to an aggressive course. This marker could also be used to access the effectiveness of the treatment.

show abstract

“…Overexpression of CD44 in colon cancer samples was found to negatively influence overall survival of colon cancer patients [33,34]; one study group found a negative association between CD44 expression and poor overall survival only for a specific variant of CD44 and, respectively, Cd44v2 [35]. The association between upregulation of CD44 in colon cancer and worse overall survival was not confirmed by other study groups [24,36], but the analysis was completed based on standard isoform of CD44 (CD44s). CD44 usage as an independent prognostic factor in colon cancer patients is not currently recommended [17], but further studies need to concentrate on specific isoforms, like the one abovementioned, in order to correctly identify its value as a prognostic marker.…”

Section: Cd44 In Colon Cancermentioning

confidence: 97%

Stem Cell Markers in Colon Cancer

Pop¹

2019

Basic Principles and Practice in Surgery

View full text Add to dashboard Cite

Colon cancer incidence is increasing in young people. Even if, so far, colon cancer had a maximum incidence in the sixth and seventh decades of life, lately its incidence in people age 50 and younger is increasing. Thus, colon cancer still represents a major health problem despite constant research made in the field. Early detection of colon cancer is mandatory for an appropriate treatment of the disease and to attain increased overall survival. Even if various stem cell markers have been studied in order to evaluate their prognostic value in colon cancer cases, results in literature are heterogeneous, and no clear consensus has been drafted so far. This paper aims to review the most important stem cell markers identified in colon cancer and to establish their role in both cancer diagnosis and progression.

show abstract

CD44 Standard Isoform; Not a Good Marker for Colon Cancer

Cited by 3 publications

References 23 publications

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis

The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer

Stem Cell Markers in Colon Cancer

Contact Info

Product

Resources

About